MX2018006282A - Profarmacos de un compuesto inhibidor de jak para el tratamiento de la enfermedad inflamatoria gastrointestinal. - Google Patents

Profarmacos de un compuesto inhibidor de jak para el tratamiento de la enfermedad inflamatoria gastrointestinal.

Info

Publication number
MX2018006282A
MX2018006282A MX2018006282A MX2018006282A MX2018006282A MX 2018006282 A MX2018006282 A MX 2018006282A MX 2018006282 A MX2018006282 A MX 2018006282A MX 2018006282 A MX2018006282 A MX 2018006282A MX 2018006282 A MX2018006282 A MX 2018006282A
Authority
MX
Mexico
Prior art keywords
jak inhibitor
prodrugs
treatment
inflammatory disease
gastrointestinal inflammatory
Prior art date
Application number
MX2018006282A
Other languages
English (en)
Inventor
D Long Daniel
A A Wilton Donna
Hudson Ryan
Loo Mandy
J Brassil Patrick
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of MX2018006282A publication Critical patent/MX2018006282A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Compuestos que son profármacos de un agente inhibidor de JAK para la administración dirigida de un inhibidor de JAK en el tracto gastrointestinal de un mamífero. Composiciones farmacéuticas que comprenden estos compuestos. Métodos para usarlos en el tratamiento de enfermedades inflamatorias gastrointestinales. Procesos e intermediarios útiles para prepararlos.
MX2018006282A 2015-11-24 2016-11-22 Profarmacos de un compuesto inhibidor de jak para el tratamiento de la enfermedad inflamatoria gastrointestinal. MX2018006282A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562259273P 2015-11-24 2015-11-24
PCT/US2016/063254 WO2017091544A1 (en) 2015-11-24 2016-11-22 Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease

Publications (1)

Publication Number Publication Date
MX2018006282A true MX2018006282A (es) 2019-01-21

Family

ID=57518004

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006282A MX2018006282A (es) 2015-11-24 2016-11-22 Profarmacos de un compuesto inhibidor de jak para el tratamiento de la enfermedad inflamatoria gastrointestinal.

Country Status (32)

Country Link
US (3) US10435428B2 (es)
EP (1) EP3380486B1 (es)
JP (2) JP6778747B2 (es)
KR (1) KR20180080330A (es)
CN (1) CN108290918B (es)
AU (1) AU2016359494B2 (es)
BR (1) BR112018010650A8 (es)
CA (1) CA3003283A1 (es)
CL (1) CL2018001345A1 (es)
CO (1) CO2018005327A2 (es)
CY (1) CY1122918T1 (es)
DK (1) DK3380486T3 (es)
EA (1) EA035816B1 (es)
ES (1) ES2784523T3 (es)
HR (1) HRP20200561T1 (es)
HU (1) HUE049775T2 (es)
IL (1) IL259076B (es)
LT (1) LT3380486T (es)
ME (1) ME03757B (es)
MX (1) MX2018006282A (es)
MY (1) MY189979A (es)
NZ (1) NZ742574A (es)
PH (1) PH12018501037A1 (es)
PL (1) PL3380486T3 (es)
PT (1) PT3380486T (es)
RS (1) RS60237B1 (es)
SG (1) SG11201803686UA (es)
SI (1) SI3380486T1 (es)
TW (1) TWI703147B (es)
UA (1) UA121270C2 (es)
WO (1) WO2017091544A1 (es)
ZA (1) ZA201802967B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3865481A1 (en) 2015-11-03 2021-08-18 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
EP3371185B1 (en) 2015-11-03 2020-09-30 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
HUE049775T2 (hu) 2015-11-24 2020-10-28 Theravance Biopharma R&D Ip Llc Gasztrointesztinális gyulladásos betegség kezelésére szolgáló JAK inhibitor vegyület elõgyógyszerei
FR3060567B1 (fr) * 2016-12-19 2019-05-24 Ecole Normale Superieure De Lyon Substrat de glycosidase fluorogene et procede de detection associe
WO2018165250A1 (en) * 2017-03-08 2018-09-13 Theravance Biopharma R&D Ip, Llc Glucuronide prodrugs of tofacitinib
NZ759764A (en) 2017-05-23 2022-07-01 Theravance Biopharma R&D Ip Llc Glucuronide prodrugs of janus kinase inhibitors
CN110662755A (zh) * 2017-05-23 2020-01-07 施万生物制药研发Ip有限责任公司 托法替尼的硫代氨基甲酸酯前药
CA3062067A1 (en) * 2017-06-05 2018-12-13 Flagship Pioneering Innovations V, Inc. Multibiotic agents and methods of using the same
US10933069B2 (en) 2018-01-05 2021-03-02 Cybrexa 1, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
KR20190110459A (ko) * 2018-03-20 2019-09-30 삼진제약주식회사 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
US20220257600A1 (en) 2018-06-20 2022-08-18 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
CN111094314B (zh) * 2018-08-15 2022-08-12 江苏豪森药业集团有限公司 含有葡糖苷酸衍生物jak抑制剂的前药及其制备方法和应用
KR20210074291A (ko) * 2018-09-06 2021-06-21 아레나 파마슈티칼스, 인크. 자가면역 및 염증성 장애의 치료에 유용한 화합물
CN109134564B (zh) * 2018-09-21 2022-03-11 合肥锐思生物医药有限公司 乳果糖糖苷衍生物、其制备方法及其用途
WO2020102519A1 (en) * 2018-11-15 2020-05-22 Janssen Biotech, Inc. Methods and compositions for prediction of response to a therapy of an inflammatory bowel disease
CN113692278A (zh) * 2018-12-19 2021-11-23 因赛特公司 用于治疗胃肠道疾病的jak1途径抑制剂
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
TW202116778A (zh) 2019-07-10 2021-05-01 美商斯布雷克薩二號公司 作為治療劑之細胞毒素之肽結合物
EP3996749A1 (en) 2019-07-10 2022-05-18 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021097074A1 (en) * 2019-11-13 2021-05-20 New York University Intestinal organoid co-culture systems and methods for treating or preventing a disease or disorder associated with immune response-mediated tissue injury
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021231272A1 (en) * 2020-05-14 2021-11-18 Theravance Biopharma R&D Ip, Llc Administration of gut-selective jak3 inhibitor
CN113943312A (zh) * 2020-07-17 2022-01-18 轶诺(浙江)药业有限公司 一类肠道裂解型共药及其制备和用途
EP4232146A4 (en) * 2020-10-22 2024-07-31 Biora Therapeutics Inc METHODS OF TREATMENT AND PREDICTION OF NON-RESPONSE TO ANTI-TNF TREATMENT IN SUBJECTS WITH DISEASES OF THE GASTROINTESTINAL TRACT
EP4351584A1 (en) * 2021-06-07 2024-04-17 The Regents of the University of California Compositions and methods for treating celiac disease
WO2023225463A2 (en) * 2022-05-14 2023-11-23 3-D Matrix, Ltd. Novel formulations for oral administration of therapeutic agents to the gastrointestinal tract
CN115073543B (zh) * 2022-07-20 2022-11-15 北京普祺医药科技股份有限公司 一种jak抑制剂的化合物前药及其制备与应用
CN117567460A (zh) * 2022-08-08 2024-02-20 明慧医药（杭州）有限公司 一种前药化合物及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993022334A1 (en) 1992-05-04 1993-11-11 Sri International Pharmaceutical compositions and methods for colonic delivery of corticosteroids
US5811388A (en) 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
KR100477818B1 (ko) 1999-12-10 2005-03-22 화이자 프로덕츠 인코포레이티드 피롤로[2,3-ｄ] 피리미딘 화합물
JP5946768B2 (ja) 2009-10-09 2016-07-06 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ ３−（４−（７Ｈ−ピロロ［２，３−ｄ］ピリミジン−４−イル）−１Ｈ−ピラゾール−１−イル）−３−シクロペンチルプロパンニトリルのヒドロキシル、ケト及びグルクロニド誘導体
EP2515913A2 (en) 2009-12-23 2012-10-31 Glycomyr Inc. Use of vitamin d glycosides and sulfates for treatment of disease
CN102724967A (zh) 2009-12-31 2012-10-10 安龙制药公司 包括可释放的脲连接体的含芳香胺化合物的聚合缀合物
AU2011213198B2 (en) * 2010-02-05 2014-04-24 Zoetis Llc Pyrrolo [ 2,3-d] pyrimidine urea compounds as JAK inhibitors
US20130109720A1 (en) 2011-11-01 2013-05-02 Hoffmann-La Roche Inc. Indole inhibitors of crac
US20140357557A1 (en) * 2013-05-31 2014-12-04 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
JP6697403B2 (ja) * 2014-06-24 2020-05-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 炎症性腸疾患の処置のための方法及び医薬組成物
HUE049775T2 (hu) 2015-11-24 2020-10-28 Theravance Biopharma R&D Ip Llc Gasztrointesztinális gyulladásos betegség kezelésére szolgáló JAK inhibitor vegyület elõgyógyszerei
AU2016379454B2 (en) 2015-12-23 2021-01-28 The University Of British Columbia Lipid-linked prodrugs
CN106496233B (zh) 2016-09-26 2018-05-15 东南大学 吡咯并嘧啶类化合物、其制备方法及其用途

Also Published As

Publication number Publication date
IL259076B (en) 2021-05-31
SI3380486T1 (sl) 2020-07-31
CY1122918T1 (el) 2021-10-29
DK3380486T3 (da) 2020-05-18
IL259076A (en) 2018-06-28
LT3380486T (lt) 2020-05-11
WO2017091544A1 (en) 2017-06-01
PL3380486T3 (pl) 2020-07-27
EP3380486B1 (en) 2020-02-19
PH12018501037A1 (en) 2019-01-28
ES2784523T3 (es) 2020-09-28
US20210179655A1 (en) 2021-06-17
US10435428B2 (en) 2019-10-08
ZA201802967B (en) 2019-04-24
BR112018010650A8 (pt) 2019-02-26
ME03757B (me) 2021-04-20
CA3003283A1 (en) 2017-06-01
JP2020196742A (ja) 2020-12-10
HUE049775T2 (hu) 2020-10-28
US20170145044A1 (en) 2017-05-25
CN108290918A (zh) 2018-07-17
US10961267B2 (en) 2021-03-30
AU2016359494A1 (en) 2018-06-14
RS60237B1 (sr) 2020-06-30
EP3380486A1 (en) 2018-10-03
SG11201803686UA (en) 2018-06-28
KR20180080330A (ko) 2018-07-11
MY189979A (en) 2022-03-22
BR112018010650A2 (pt) 2018-11-13
PT3380486T (pt) 2020-05-22
TW201720827A (zh) 2017-06-16
CO2018005327A2 (es) 2018-05-31
EA035816B1 (ru) 2020-08-14
HRP20200561T1 (hr) 2020-06-26
CL2018001345A1 (es) 2018-06-22
TWI703147B (zh) 2020-09-01
NZ742574A (en) 2018-11-30
US11608354B2 (en) 2023-03-21
US20190389895A1 (en) 2019-12-26
EA201891248A1 (ru) 2018-10-31
UA121270C2 (uk) 2020-04-27
JP6778747B2 (ja) 2020-11-04
AU2016359494B2 (en) 2021-01-07
JP2019501133A (ja) 2019-01-17
CN108290918B (zh) 2021-06-08

Similar Documents

Publication Publication Date Title
PH12018501037A1 (en) Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
MY195427A (en) Jak Kinase Inhibitor Compounds for Treatment of Respiratory Disease
PH12017500828A1 (en) Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
NZ769042A (en) Compositions and methods for treating cns disorders
PH12017500914A1 (en) Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
MX2021004492A (es) Composiciones para el tratamiento de trastornos del snc.
PH12016502179A1 (en) Inhibitors of lysine specific demethylase-1
EA201691940A1 (ru) Новые соединения
PH12016501750A1 (en) Human plasma kallikrein inhibitors
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
MX2016013049A (es) Inhibidores de autotaxina espirociclicos sustituidos.
MY197440A (en) Heteroamatic compounds as btk inhibitors
PH12016501462A1 (en) Neprilysin inhibitors
NZ759764A (en) Glucuronide prodrugs of janus kinase inhibitors
MX2017015734A (es) Profarmacos que comprenden un conjugado de acido hialuronico enlazador agonista dual de glp-1/glucagon.
IL287523A (en) Useful preparations for the treatment of Pompe disease
PH12019502693A1 (en) Heteroaromatic compounds as vanin inhibitors
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
EA202191548A1 (ru) Ингибиторы плазменного калликреина человека
MX2018002177A (es) Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo.
EA201990686A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
EA202091668A3 (ru) Ингибиторы калликреина плазмы человека